A clinical study of pancreatic ductal adenocarcinoma showed that oral CCR2 inhibitor PF‐04136309 combined with chemotherapy (FOLFIRINOX) could achieve local tumor control in 32 of 33 patients (97%).31 The gene discussed is CCR2; the disease is pancreatic ductal adenocarcinoma.